Claro (Canada)This page contains information on Claro for veterinary use.
The information provided typically includes the following:
- Claro Indications
- Warnings and cautions for Claro
- Direction and dosage information for Claro
ClaroThis treatment applies to the following species:
Florfenicol, Terbinafine hydrochloride, and Mometasone furoate Otic Solution
VETERINARY USE ONLY
CLARO contains 16.6 mg/mL florfenicol, 14.8 mg/mL terbinafine (equivalent to 16.6 mg/mL terbinafine hydrochloride) and 2.2 mg/mL mometasone furoate.
Antibiotic, antifungal and anti-inflammatory.
CLARO is indicated for the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).
Dosage and Administration
Shake before use.
CLARO should be administered by veterinary personnel in clinic. Care should be taken to prevent accidental exposure to the eyes (See CAUTIONS and WARNINGS).
Administer one dose (1 dropperette) per affected ear. The duration of effect should last 30 days.
1. Clean and dry the external ear canal before administering the product.
2. Verify the tympanic membrane is intact prior to administration.
3. Remove single dose dropperette from the package.
4. While holding the dropperette in an upright position, remove the cap from the dropperette.
5. Turn the cap over and push the other end of the cap onto the tip of the dropperette.
6. Twist the cap to break the seal and then remove cap from the dropperette.
7. Screw the applicator nozzle onto the dropperette.
8. Insert the tapered tip of the dropperette into the affected external ear canal and squeeze to instill the entire contents (1 mL) into the affected ear.
9. Gently massage the base of the ear to allow distribution of the solution.
10. Repeat with other ear as prescribed.
Cleaning the ear after dosing may affect product effectiveness.
Do not use in dogs with known tympanic membrane perforation (see CAUTIONS).
Do not administer orally.
Do not use in dogs with known or suspected hypersensitivity to florfenicol, terbinafine hydrochloride, mometasone furoate, other corticosteroids or any excipients.
The use of CLARO in dogs with perforated tympanic membranes has not been evaluated. The integrity of the tympanic membrane should be confirmed before administering the product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment.
Use of topical otic corticosteroids has been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs (see ANIMAL SAFETY).
The safe use of CLARO in dogs used for breeding purposes, during pregnancy or lactation has not been evaluated.
CLARO should be used with caution in dogs with impaired hepatic function (see ANIMAL SAFETY).
Caution should be used to prevent the medication from getting into the eyes of the dog being treated. In case of exposure to the eye, rinse with abundant quantities of water. If any eye irritation is seen after treatment, seek veterinary care.
Not for use in humans. In case of accidental ingestion, contact a physician immediately. When handling this product, special cautions should be taken to avoid oral exposure and direct contact with eyes or skin. May cause eye irritation. In case of accidental contact with eyes, rinse with abundant quantities of water and seek medical attention. In case of accidental skin contact, wash area thoroughly with water. Humans with known hypersensitivity to florfenicol, terbinafine hydrochloride, or mometasone furoate should not handle this product. Keep out of reach of children.
Although all adverse reactions are not reported, the following information is based on voluntary post-approval drug experience reporting. It is generally recognized that this results in significant under-reporting. The adverse events listed here reflect reporting and not necessarily causality.
By system, adverse events are listed in decreasing order of frequency. By system, these clinical signs were reported for CLARO rarely (1 -10 reports per 10,000 doses sold) or very rarely (<1 report per 10,000 doses sold) and include:
Ear and labyrinth disorders: ear discharge, head shake, ear infection
Systemic disorders: lethargy, anorexia
Skin and appendages disorders: pruritus
Application site disorders: application site erythema
Neurological disorders: ataxia, nystagmus
Digestive tract disorders: emesis
To report suspected adverse drug events or for technical assistance, contact Elanco Canada Limited at 1-800-265-5475.
CLARO Otic Solution is a fixed combination of three active substances: florfenicol (antibiotic), terbinafine (antifungal) and mometasone furoate (steroidal anti-inflammatory). Florfenicol is a bacteriostatic antibiotic which acts by inhibiting protein synthesis. Terbinafine is an antifungal which selectively inhibits the early synthesis of ergosterol. Mometasone furoate is a glucocorticosteroid with anti-inflammatory activity.
The compatibility and additive effect of each of the components in CLARO solution was demonstrated in a component effectiveness and non-interference study in vitro study of organisms collected from clinical cases of otitis externa in dogs enrolled in the clinical effectiveness study determined that florfenicol and terbinafine hydrochloride inhibit the growth of bacteria and yeast commonly associated with otitis externa in dogs. No consistent synergistic or antagonistic effect of the two antimicrobials was demonstrated. The addition of mometasone furoate to the combination did not impair antimicrobial activity to any clinically significant extent.
In a field study (see EFFECTIVENESS), at least 10 isolates from successfully treated cases were obtained for S. pseudintermedius and M. pachydermatis.
SAFETY AND EFFICACY INFORMATION:
In a well-controlled, double-masked field study, CLARO was evaluated against a vehicle control in 221 dogs with otitis externa. One hundred and forty six dogs were treated with CLARO and 75 dogs were treated with the vehicle control. All dogs were evaluated for safety. Treatment (1 mL) was administered once on Day 0 to the affected ear(s). Prior to treatment, the ear(s) was cleaned with saline. The dogs were evaluated on Days 0, 7, 14, and 30. Blood work and urinalysis were obtained on Day 0 pre-treatment and Day 30 at study completion. Four clinical signs associated with otitis externa were evaluated: erythema, exudate, swelling, and ulceration. Success was based on clinical improvement at Day 30. Of the 183 dogs included in the effectiveness evaluation, 72.5% of dogs administered CLARO solution were successfully treated, compared to 11.1% of the dogs in the vehicle-control group (p=0.0001).
In a target animal safety study, CLARO was administered aurally to 12-week-old Beagle puppies (4 dogs/sex/group) at 0X, 1X, 3X, and 5X the recommended dose once every 2 weeks for a total dosing period of 28 days (3 times the treatment duration). No clinically relevant treatment-related findings were noted in hearing tests, body weight, weight gain, or food consumption. CLARO administration was associated with post-treatment ear wetness or clear aural exudate, increased absolute neutrophil count, decreased absolute lymphocyte and eosinophil counts, suppression of the adrenal cortical response to adrenocorticotropic hormone (ACTH) stimulation, decreased adrenal weight and atrophy of the adrenal cortex, increased liver weight with hepatocellular enlargement/cytoplasmic change, and decreased thymus weight. Other potentially treatment-related effects included mild changes to aspartate aminotransferase, total protein, inorganic phosphorus, creatinine, and calcium.
Store at 15°C-25°C. Excursions permitted to 30°C.
CLARO is supplied in a single-use dropperette in a blister. Each dropperette contains one 1 mL dose.
CLARO is available in cartons of 2 or 10 dropperettes.
Elanco Canada Limited, 150 Research Lane, Suite 120, Guelph, Ontario N1G 4T2
DATE: August 2021
CLARO, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
©2021 Elanco or its affiliates.
150 RESEARCH LANE, SUITE 120, GUELPH, ON, N1G 4T2
Copyright © 2022 Animalytix LLC. Updated: 2021-12-02